Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 561819, 11 pages
http://dx.doi.org/10.1155/2015/561819
Research Article

Targeted Next-Generation Sequencing Reveals Hot Spots and Doubly Heterozygous Mutations in Chinese Patients with Familial Cardiomyopathy

1Faculty of Life Science and Technology, Center for Molecular Diagnosis in Yunnan Province, Kunming University of Science and Technology, Kunming 650500, China
2The Cardiac Department, The First Hospital of Yunnan Province, Kunming 650034, China

Received 22 March 2015; Revised 30 May 2015; Accepted 31 May 2015

Academic Editor: Sakthivel Sadayappan

Copyright © 2015 Yue Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z.-Y. Wu, G.-X. Zhao, W.-J. Chen et al., “Mutation analysis of 218 Chinese patients with Wilson disease revealed no correlation between the canine copper toxicosis gene MURR1 and Wilson disease,” Journal of Molecular Medicine, vol. 84, no. 5, pp. 438–442, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. James, Y. Zhang, H. Osinska et al., “Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy,” Circulation Research, vol. 87, no. 9, pp. 805–811, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. B. J. Maron, J. J. Doerer, T. S. Haas, D. M. Tierney, and F. O. Mueller, “Sudden deaths in young competitive athletes analysis of 1866 deaths in the United States, 1980–2006,” Circulation, vol. 119, no. 8, pp. 1085–1092, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. B. J. Gersh, B. J. Maron, R. O. Bonow et al., “2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” Journal of the American College of Cardiology, vol. 58, no. 25, pp. e212–e260, 2011. View at Publisher · View at Google Scholar
  5. B. J. Maron, “Hypertrophic cardiomyopathy: an important global disease,” The American Journal of Medicine, vol. 116, no. 1, pp. 63–65, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Watkins, L. Thierfelder, R. Anan et al., “Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy,” The American Journal of Human Genetics, vol. 53, no. 6, pp. 1180–1185, 1993. View at Google Scholar · View at Scopus
  7. Y. M. Pinto, A. A. A. M. Wilde, I. A. W. van Rijsingen, I. Christiaans, R. H. L. Deprez, and P. M. Elliott, “Clinical utility gene card for: hypertrophic cardiomyopathy (type 1–14),” European Journal of Human Genetics, vol. 19, no. 8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. W. D. Kuster and S. Sadayappan, “MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation,” Pflügers Archiv—European Journal of Physiology, vol. 466, no. 2, pp. 207–213, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. G. Colombo, N. Botto, S. Vittorini, U. Paradossi, and M. G. Andreassi, “Clinical utility of genetic tests for inherited hypertrophic and dilated cardiomyopathies,” Cardiovascular Ultrasound, vol. 6, article 62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. R. E. Hershberger, D. J. Hedges, and A. Morales, “Dilated cardiomyopathy: the complexity of a diverse genetic architecture,” Nature Reviews Cardiology, vol. 10, no. 9, pp. 531–547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Kubo, H. Kitaoka, M. Okawa et al., “Genetic screening and double mutation in Japanese patients with hypertrophic cardiomyopathy,” Circulation Journal, vol. 75, no. 11, pp. 2654–2659, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Botto, S. Vittorini, M. G. Colombo et al., “A novel LMNA mutation (R189W) in familial dilated cardiomyopathy: Evidence for a ‘hot spot’ region at exon 3: a case report,” Cardiovascular Ultrasound, vol. 8, no. 1, article 9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Mestroni, B. Maisch, W. J. McKenna et al., “Guidelines for the study of familial dilated cardiomyopathies,” European Heart Journal, vol. 20, no. 2, pp. 93–102, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Li, B. Handsaker, A. Wysoker et al., “The sequence alignment/map format and SAMtools,” Bioinformatics, vol. 25, no. 16, pp. 2078–2079, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Wang, M. Li, and H. Hakonarson, “ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data,” Nucleic Acids Research, vol. 38, no. 16, article e164, Article ID gkq603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. I. A. Adzhubei, S. Schmidt, L. Peshkin et al., “A method and server for predicting damaging missense mutations,” Nature Methods, vol. 7, no. 4, pp. 248–249, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Kumar, S. Henikoff, and P. C. Ng, “Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm,” Nature Protocols, vol. 4, no. 7, pp. 1073–1081, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. M. Schwarz, C. Rödelsperger, M. Schuelke, and D. Seelow, “MutationTaster evaluates disease-causing potential of sequence alterations,” Nature Methods, vol. 7, no. 8, pp. 575–576, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Hirtle-Lewis, K. Desbiens, I. Ruel et al., “The genetics of dilated cardiomyopathy: a prioritized candidate gene study of LMNA, TNNT2, TCAP, and PLN,” Clinical Cardiology, vol. 36, no. 10, pp. 628–633, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Sikkema-Raddatz, L. F. Johansson, E. N. Boer et al., “Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics,” Human Mutation, vol. 34, no. 7, pp. 1035–1042, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Sadayappan and P. P. de Tombe, “Cardiac myosin binding protein-C as a central target of cardiac sarcomere signaling: a special mini review series,” European Journal of Physiology, vol. 466, no. 2, pp. 195–200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Sadayappan, N. Finley, J. W. Howarth et al., “Role of the acidic N′ region of cardiac troponin I in regulating myocardial function,” The FASEB Journal, vol. 22, no. 4, pp. 1246–1257, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Wen, J. R. Pinto, A. V. Gomes et al., “Functional consequences of the human cardiac troponin I hypertrophic cardiomyopathy mutation R145G in transgenic mice,” The Journal of Biological Chemistry, vol. 283, no. 29, pp. 20484–20494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. B. J. Maron, H. Niimura, S. A. Casey et al., “Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations,” Journal of the American College of Cardiology, vol. 38, no. 2, pp. 315–321, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Niimura, L. L. Bachinski, S. Sangwatanaroj et al., “Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy,” The New England Journal of Medicine, vol. 338, no. 18, pp. 1248–1257, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Perrot, S. Hussein, V. Ruppert et al., “Identification of mutational hot spots in LMNA encoding lamin A/C in patients with familial dilated cardiomyopathy,” Basic Research in Cardiology, vol. 104, no. 1, pp. 90–99, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Richard, P. Charron, L. Carrier et al., “Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy,” Circulation, vol. 107, no. 17, pp. 2227–2232, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Song, M.-P. Dubé, J. Lim, I. Hwang, I. Lee, and J.-J. Kim, “Lamin A/C mutations associated with familial and sporadic cases of dilated cardiomyopathy in Koreans,” Experimental and Molecular Medicine, vol. 39, no. 1, pp. 114–120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Hermida-Prieto, L. Monserrat, A. Castro-Beiras et al., “Familial dilated cardiomyopathy and isolated left ventricular noncompaction associated with lamin A/C gene mutations,” The American Journal of Cardiology, vol. 94, no. 1, pp. 50–54, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Arbustini, A. Pilotto, A. Repetto et al., “Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease,” Journal of the American College of Cardiology, vol. 39, no. 6, pp. 981–990, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. S. B. Parks, J. D. Kushner, D. Nauman et al., “Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy,” American Heart Journal, vol. 156, no. 1, pp. 161–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Pethig, J. Genschel, T. Peters et al., “LMNA mutations in cardiac transplant recipients,” Cardiology, vol. 103, no. 2, pp. 57–62, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Sylvius, Z. T. Bilinska, J. P. Veinot et al., “In vivo and in vitro examination of the functional significances of novel lamin gene mutations in heart failure patients,” Journal of Medical Genetics, vol. 42, no. 8, pp. 639–647, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Kärkkäinen, E. Reisseil, T. Heliö et al., “Novel mutations in the lamin A/C gene in heart transplant recipients with end stage dilated cardiomyopathy,” Heart, vol. 92, no. 4, pp. 524–526, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. K. E. Berge and T. P. Leren, “Genetics of hypertrophic cardiomyopathy in Norway,” Clinical Genetics, vol. 86, no. 4, pp. 355–360, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Frisso, G. Limongelli, G. Pacileo et al., “A child cohort study from southern Italy enlarges the genetic spectrum of hypertrophic cardiomyopathy,” Clinical Genetics, vol. 76, no. 1, pp. 91–101, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Arad, M. Penas-Lado, L. Monserrat et al., “Gene mutations in apical hypertrophic cardiomyopathy,” Circulation, vol. 112, no. 18, pp. 2805–2811, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Zou, J. Wang, X. Liu et al., “Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy,” Molecular Biology Reports, vol. 40, no. 6, pp. 3969–3976, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Carballo, P. Robinson, R. Otway et al., “Identification and functional characterization of cardiac troponin i as a novel disease gene in autosomal dominant dilated cardiomyopathy,” Circulation Research, vol. 105, no. 4, pp. 375–382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Frazier, D. P. Judge, S. P. Schulman, N. Johnson, K. W. Holmes, and A. M. Murphy, “Familial hypertrophic cardiomyopathy associated with cardiac β-myosin heavy chain and troponin I mutations,” Pediatric Cardiology, vol. 29, no. 4, pp. 846–850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. S. L. Van Driest, E. G. Ellsworth, S. R. Ommen, A. J. Tajik, B. J. Gersh, and M. J. Ackerman, “Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy,” Circulation, vol. 108, no. 4, pp. 445–451, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. J.-O. Choi, C.-W. Yu, J. C. Nah et al., “Long-term outcome of 4 Korean families with hypertrophic cardiomyopathy caused by 4 different mutations,” Clinical Cardiology, vol. 33, no. 7, pp. 430–438, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Mogensen, R. T. Murphy, T. Kubo et al., “Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 44, no. 12, pp. 2315–2325, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Kimura, H. Harada, J.-E. Park et al., “Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy,” Nature Genetics, vol. 16, no. 4, pp. 379–382, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Bonne, E. Mercuri, A. Muchir et al., “Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene,” Annals of Neurology, vol. 48, no. 2, pp. 170–180, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. J. C. Moon, J. Mogensen, P. M. Elliott et al., “Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I,” Heart, vol. 91, no. 8, pp. 1036–1040, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. J. P. Kaski, P. Syrris, M. T. T. Esteban et al., “Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy,” Circulation: Cardiovascular Genetics, vol. 2, no. 5, pp. 436–441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Erdmann, S. Daehmlow, S. Wischke et al., “Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy,” Clinical Genetics, vol. 64, no. 4, pp. 339–349, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. A. van den Wijngaard, P. Volders, J. P. van Tintelen et al., “Recurrent and founder mutations in the Netherlands: cardiac troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy,” Netherlands Heart Journal, vol. 19, no. 7-8, pp. 344–351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Niimura, K. K. Patton, W. J. McKenna et al., “Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly,” Circulation, vol. 105, no. 4, pp. 446–451, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. A. V. Gomes and J. D. Potter, “Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene,” Molecular and Cellular Biochemistry, vol. 263, no. 1, pp. 99–114, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. M. R. G. Taylor, P. R. Fain, G. Sinagra et al., “Natural history of dilated cardiomyopathy due to lamin A/C gene mutations,” Journal of the American College of Cardiology, vol. 41, no. 5, pp. 771–780, 2003. View at Publisher · View at Google Scholar
  53. D. Fatkin, C. Macrae, T. Sasaki et al., “Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease,” The New England Journal of Medicine, vol. 341, no. 23, pp. 1715–1724, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Wang, J. Wang, W. Zheng et al., “Mutation Glu82Lys in lamin A/C gene is associated with cardiomyopathy and conduction defect,” Biochemical and Biophysical Research Communications, vol. 344, no. 1, pp. 17–24, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. J. P. van Tintelen, R. M. W. Hofstra, H. Katerberg et al., “High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics,” The American Heart Journal, vol. 154, no. 6, pp. 1130–1139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. C.-C. Lai, Y.-H. Yeh, W.-P. Hsieh et al., “Whole-exome sequencing to identify a novel LMNA gene mutation associated with inherited cardiac conduction disease,” PLoS ONE, vol. 8, no. 12, Article ID e83322, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Roncarati, C. Viviani Anselmi, P. Krawitz et al., “Doubly heterozygous LMNA and TTN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy,” European Journal of Human Genetics, vol. 21, no. 10, pp. 1105–1111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. L.-P. Sun, L. Wang, H. Wang, Y.-H. Zhang, and J.-L. Pu, “Connexin 43 remodeling induced by LMNA gene mutation Glu82Lys in familial dilated cardiomyopathy with atrial ventricular block,” Chinese Medical Journal, vol. 123, no. 8, pp. 1058–1062, 2010. View at Publisher · View at Google Scholar · View at Scopus